We believe that the decision on relapse of anti-LGI1 encephalitis must be carefully made based not only on radiological or serological biomarkers but also on neurological assessment of disease-specific symptoms, such as FBDS or a substantial rise in the CASE score. The gene discussed is LGI1; the disease is viral encephalitis.